ArticleNeuropsychiatric disease and treatment2026
Disease Awareness, Care-Seeking Behavior, and Symptom Burden Among Japanese Patients with Generalized Anxiety Disorder: Results from a Web-Based Questionnaire of Clinical Trial Participants.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study was conducted among Japanese patients with generalized anxiety disorder (GAD) who had participated in a clinical trial to investigate their level of disease awareness, past medical care-seeking behavior and diagnoses, symptoms and impact on daily life, perceptions of diagnosis and clinical assessment, and changes after trial participation. The patients' first-hand experiences related to symptoms and disease burden were collected through open-ended responses. Patients and Methods: This was a quantitative (descriptive observational) study using a web-based questionnaire conducted from April 23 to May 25, 2025. Patients diagnosed with GAD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and previously enrolled in Study B2411367, a clinical trial of venlafaxine, a serotonin-norepinephrine reuptake inhibitor, were eligible. Results: Data from 98 respondents were analyzed. The most frequently reported GAD symptoms at trial entry included excessive anxiety or worry (99.0%), becoming fatigued easily (86.7%), and sleep problems (82.7%). Over half of respondents (53.1%) identified work or studying as the most affected area of daily life, describing impaired concentration, reduced efficiency, and physical strain. Regarding disease awareness, 72.4% of respondents had never heard of GAD and 71.4% attributed their anxiety to their personality. Only 11.2% had sought medical care before trial participation, with depression being the most frequent diagnosis (36.4%) and only 9.1% having been diagnosed with GAD. Conclusion: Many patients with GAD were unaware of the disease name before trial entry and had symptoms that impacted daily life. The patients' first-hand accounts provided deeper insight into their burden. The findings highlight the unmet needs among Japanese patients with GAD who participated in a clinical trial and the situation of low public disease awareness and limited recognition in clinical settings. Efforts to increase awareness of GAD may help facilitate earlier diagnosis and broaden access to appropriate treatment. Clinical Trial Registration: UMIN000057689.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.